In Brief: Boston Scientific/CorTrak
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific/CorTrak: Boston Scientific gains exclusive international distribution rights to CorTrak's coronary iontophoresis drug delivery technology. CorTrak's technology, currently in clinical trials, will initially be used for treating and/or preventing angioplasty associated complications. The system "uses a catheter and an electronic field to transport drugs through difficult tissue barriers and into the cells...more quickly and deeply than conventional drug delivery systems," CorTrak says...
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.